Discovery Lab, Pharmacia, Quintiles deal

QTRN and DSCO will market and distribute DSCO’s surfaxin lung surfactant to treat respiratory distress syndrome (RDS) in premature newborns and meconium aspiration syndrome (MAS) in full-term newborns, in addition to adult respiratory distress syndrome (ARDS). Surfaxin is in Phase III testing for RDS and MAS and Phase II trials for ARD. QTRN investment group, PharmaBio Development, will buy $3 million in DSCO stock at $3.79, extend an $8.5-$10 million line of credit to fund pre-market launch costs and fund surfaxin sales and marketing costs for 7 years. PharmaBio is eligible for 10 years of royalties. Surfaxin is a humanized peptide-based synthetic surfactant that mimics protein B. ...